Develops psilocybin-based therapy (COMP360) combined with psychological support for treatment-resistant depression.
Develops psilocybin-based therapy (COMP360) combined with psychological support for treatment-resistant depression.
Has no product to sell yet, so it is funded by share sales, and its value rests on getting COMP360 approved and then paid for by insurers. The treatment is a supervised dosing session with trained therapists rather than a pill taken at home, so a launch would need clinics set up for it. The company is based in London.
Moat: narrow (IP / patents, regulatory licence). First mover with patented synthetic psilocybin formulation and specialized therapy-delivery infrastructure.
Headquarters: London, UK · Founded: 2016 · Employees: 156
Size COMPASS Pathways Plc Sponsored ADR (CMPS) is a United States Health Care company (Biotechnology) with a market value of $1.15B, the 2146th largest of 3,085 United States companies the cockpit tracks. Shares closed at $8.12 on 18 Nov 2026.
Performance Over six months the shares fell 25.3%, against -17.5% for the median peer and -2.2% for the United States market (cap-weighted) — 7th lowest of 19 in its peer set.
Short interest Short interest is 12.1% of the free float (30 Oct 2026).
Next results Next results expected around 4 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | -$5,991 | -$216,505 | -$233,098 | -$242,938 | -$329,796 |
| EBITDA | -$198M | -$179M | -$178M | -$137M | -$110M |
| Net income | -$280M | -$289M | -$155M | -$119M | -$91.4M |
| Free cash flow | -$177M | -$158M | -$119M | -$97.8M | -$106M |
| Capital expenditure | $0 | $0 | $0 | $66,256 | $595,632 |
| Total debt | $54.4M | $35.0M | $32.2M | $33.0M | $1.93M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| COMPASS Pathways Plc Sponsored ADR CMPS | $1.15B | -25% | n/a | n/a | n/a | n/a |
| AtaiBeckley ATAI | n/a | +81% | n/a | n/a | n/a | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | CMPS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -31.8% | -8.6% | 3rd lowest of 21 |
| 6-month return | -25.3% | -17.5% | 7th lowest of 19 |
| Distance from 52-week high | -48.8% | -45.0% | 9th lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| COMPASS Pathways Plc Sponsored ADR CMPS | United States | $1.15B | -25% | n/a | n/a | n/a | n/a | n/a |
| Kardigan KARD | United States | $1.15B | n/a | n/a | n/a | n/a | n/a | n/a |
| Akums Drugs and Pharmaceuticals AKUMS.NS | India | $1.21B | +38% | +18% | 10% | 2.0× | 15.3% | +9.9% |
| Vor Biopharma VOR | United States | $1.10B | +15% | n/a | n/a | n/a | n/a | n/a |
| Mineralys Therapeutics MLYS | United States | $1.22B | -52% | n/a | n/a | n/a | n/a | n/a |
| Liaoning Chengda Biotechnology 688739.SS | China | $1.22B | -14% | -9% | 0% | 2.2× | 6.6% | -7.0% |
| Jade Biosciences JBIO | United States | $1.07B | -34% | n/a | n/a | n/a | n/a | n/a |
| Pacific Shuanglin Bio-pharmacy 000403.SZ | China | $1.24B | -21% | +1% | 10% | 3.5× | n/a | n/a |
| Duality Biotherapeutics 9606.HK | Hong Kong | $1.06B | -58% | -5% | -181% | 5.6× | n/a | n/a |
| Hualan Biological Vaccine 301207.SZ | China | $1.25B | -29% | -28% | -7% | 9.0× | 33.2% | -13.1% |
| Daan Gene 002030.SZ | China | $1.05B | -17% | +1% | -81% | 8.0× | 4.8% | -32.3% |
| Guangzhou Wondfo Biotech 300482.SZ | China | $1.05B | -18% | -24% | -2% | 2.9× | 14.3% | -5.8% |
| Alto Neuroscience ANRO | United States | $1.04B | +25% | n/a | n/a | n/a | n/a | n/a |
| Inhibrx Biosciences INBX | United States | $1.02B | -37% | +43% | -6,287% | 551.0× | n/a | n/a |
| Taysha Gene Therapies TSHA | United States | $1.30B | -27% | -13% | -2,998% | 170.1× | n/a | n/a |
| Novavax NVAX | United States | $1.31B | -14% | -61% | -17% | 2.4× | n/a | n/a |
| Zhuhai Trinomab Pharmaceutical 688806.SS | China | $1.32B | n/a | +238% | -1,196% | 164.8× | n/a | n/a |
| SpyGlass Pharma SGP | United States | $993M | +36% | n/a | n/a | n/a | n/a | n/a |
| Changchun BCHT Biotechnology 688276.SS | China | $992M | -2% | +2% | -29% | 9.9× | n/a | n/a |
| Nuvation Bio NUVB | United States | $1.34B | -16% | +654% | -61% | 5.7× | n/a | n/a |
| Generate Biomedicines GENB | United States | $1.34B | -20% | +56% | -737% | 31.7× | n/a | n/a |